Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Merck stories

Nov 15, 2026

J&J in talks to acquire eye disease biotech for up to $3.4bn

Johnson & Johnson is poised to acquire a privately held eye disease drug developer in a deal valued at up to $3.4 billion, according to the Financial Times.

Nov 15, 2026·2 sources
00
Oct 30, 2026

Norrin treatment prevents vision loss in diabetic rats, study finds

Research shows that treatment with norrin helps maintain healthy blood vessels in the retina and preserves vision in diabetic rats, offering potential hope for treating diabetic retinopathy, a complication affecting over 100 million people in the U.S.

Oct 30, 2026·2 sources
00
Oct 28, 2026

Genmab's petosemtamab cuts death risk by half in head and neck cancer trial

Danish drugmaker Genmab reported its experimental drug petosemtamab reduced the risk of death by 50% in a late-stage study of patients with head and neck cancer, sending US-traded shares up 28%.

Oct 28, 2026·3 sources
00
Oct 26, 2026

Merck drug extends survival in endometrial cancer, wins FDA priority review

Merck's experimental antibody-drug conjugate reduced death risk by one-third in advanced endometrial cancer patients and received FDA priority review based on late-stage trial data.

Oct 26, 2026·3 sources
00
Oct 22, 2026

Moderna and Merck melanoma vaccine cuts death or recurrence risk by 42% in phase 3 trial

The mRNA-based personalized cancer vaccine combined with Keytruda reduced the risk of melanoma death or recurrence by 42% in a late-stage trial, though leaked data triggered a sell-off in Moderna shares despite meeting expectations.

Oct 22, 2026·5 sources
00
Oct 14, 2026

Merck CEO says cancer vaccine with Moderna will become faster to manufacture

Merck CEO Rob Davis said he expects the personalized cancer vaccine being developed with Moderna to have a shortened production timeline from its current six-week manufacturing period. The announcement comes after the companies reported promising late-stage trial results in August for the mRNA vaccine combined with immunotherapy for melanoma.

Oct 14, 2026·4 sources
00
Oct 7, 2026

Merck blocked from selling injectable Keytruda in Europe after patent ruling

A Dutch patent court ruled in favor of Halozyme against Merck, ordering the drugmaker to halt manufacture and sale of injectable Keytruda in eight European countries due to patent infringement.

Oct 7, 2026·2 sources
00
Oct 5, 2026

Vaxcyte pneumococcal vaccine succeeds in Phase 3 trial

Vaxcyte's experimental pneumococcal vaccine generated immune responses comparable to Pfizer and Merck vaccines in a Phase 3 trial, positioning it to compete in the lucrative vaccine market.

Oct 5, 2026·3 sources
00
Oct 1, 2026

HRSA approves 10 drugmakers for revised 340B rebate pilot program covering 21 drugs

The Trump administration released a list of 10 pharmaceutical companies, including AbbVie, Merck, and Pfizer, that will be allowed to shift from upfront discounts to after-the-fact rebates on 21 drugs in the 340B drug discount program starting January 1. The revised pilot program includes more manufacturers than the administration's first attempt at a rebate program.

Oct 1, 2026·3 sources
00
Sep 30, 2026

Merck's experimental skin disease drug succeeds in mid-stage study

Merck reported positive mid-stage trial results for an experimental drug targeting a painful skin disease, marking progress in the company's dermatology pipeline.

Sep 30, 2026·2 sources
00
Sep 28, 2026

Merck discontinues Recarbrio antibiotic despite concerns over superbug resistance

Merck has discontinued Recarbrio, a crucial antibiotic used to treat drug-resistant infections, raising concerns among health experts about the availability of treatments for superbug resistance at a time when antimicrobial resistance remains a growing public health threat.

Sep 28, 2026·2 sources
00

Merck licenses KRAS G12D cancer drug from SciBrunch for $400 million upfront

Merck agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global rights to an experimental cancer drug targeting the KRAS G12D mutation, continuing a trend of U.S. drugmakers licensing China-developed therapies.

Sep 28, 2026·3 sources
00

Merck and Daiichi abandon accelerated approval plans for lung cancer ADC

Merck and Daiichi Sankyo ended plans to seek accelerated FDA approval for their antibody-drug conjugate I-DXd in lung cancer after the agency indicated existing data wouldn't support the pathway, erasing a competitive advantage over rivals.

Sep 28, 2026·2 sources
00
Sep 24, 2026

Merck's remigromig meets primary endpoint in diabetic macular edema trial amid safety concerns

Merck announced that remigromig, a tri-specific antibody acquired in a $1.3 billion buyout, achieved its primary endpoint in the pivotal Phase 2b/3 BRUNELLO trial for diabetic macular edema. However, language regarding the drug's safety profile has raised concerns among analysts.

Sep 24, 2026·4 sources
00
Aug 28, 2026

Moderna raises $2.6B following major cancer vaccine trial success

Moderna completed an upsized note offering to support its cancer work shortly after achieving a significant win in a crucial clinical study of its mRNA cancer vaccine developed with Merck.

Aug 28, 2026·2 sources
00
Aug 20, 2026

Moderna gains $45 billion in market value after cancer vaccine breakthrough

Moderna's stock surged following positive data on its mRNA cancer vaccine developed with Merck, restoring investor confidence and bringing shares to levels not seen since 2024.

Aug 20, 2026·2 sources
00
Aug 19, 2026

Moderna and Merck's mRNA cancer vaccine reduces melanoma recurrence in late-stage trial

Moderna and Merck announced positive results from a Phase 3 trial showing their personalized mRNA cancer vaccine, combined with Keytruda, significantly reduced melanoma recurrence and spread. The companies aim to bring the therapy to market in 2027.

Aug 19, 2026·6 sources
00
Aug 4, 2026

Merck's anti-TL1A antibody shows mixed Phase 2 results in hidradenitis suppurativa and lung disease

Merck's anti-TL1A antibody from its 2023 Prometheus Biosciences acquisition delivered positive mid-stage results in hidradenitis suppurativa but failed to meet endpoints in a rare lung disease trial. The company disclosed the mixed Phase 2 results alongside its second-quarter earnings.

Aug 4, 2026·2 sources
00

Merck raises 2026 sales outlook on strength of newer drugs including Winrevair

Merck beat second-quarter estimates and boosted its 2026 sales forecast after strong demand for newer drugs like Winrevair helped drive revenues higher, though the company cut profit guidance due to deal-related charges.

Aug 4, 2026·2 sources
00
Jul 30, 2026

Merck-Wellcome Joint Venture to Manufacture Experimental Ebola Vaccine for Congo Outbreak

Hilleman Laboratories, a Singapore-based partnership between Merck and Wellcome, is preparing to produce doses of an experimental vaccine targeting the rare Bundibugyo strain of Ebola amid a fast-spreading outbreak in the Democratic Republic of Congo.

Jul 30, 2026·1 source
00
Jul 24, 2026

Merck licenses experimental once-monthly HIV pill to seven generic manufacturers for 129 countries

Merck signed voluntary licensing agreements with seven generic drug manufacturers—including Aspen Pharmacare, Cipla, Aurobindo, and Viatris—to produce and sell lower-cost versions of alimatravir, its experimental once-monthly oral HIV pill, in 129 low- and middle-income countries. The drug is currently in late-stage development.

Jul 24, 2026·6 sources
00
Jul 21, 2026

Gilead Sciences and Merck's Once-Weekly HIV Pill Maintains Viral Suppression in Phase 3 Trials

Gilead Sciences and Merck announced that their experimental once-weekly HIV pill combining islatravir and lenacapavir successfully maintained viral suppression at 48 weeks in two Phase 3 trials (ISLEND-1 and ISLEND-2) involving 1,209 adults with virologically suppressed HIV. The results support regulatory filings for what could become the first once-weekly oral HIV treatment regimen.

Jul 21, 2026·7 sources
00
Jul 16, 2026

Merck wins FDA approval for first oral PCSK9 cholesterol pill

Merck received FDA approval for its oral PCSK9 inhibitor cholesterol pill, the first of its kind, offering a more convenient alternative to existing injectable therapies for high-risk patients.

Jul 16, 2026·4 sources
00
May 2, 2026

FDA Approves Merck's Idvynso, New Once-Daily Two-Drug HIV Treatment Tablet

The FDA has approved Merck's Idvynso (doravirine/islatravir), a once-daily, two-drug single tablet for treating HIV-1 infection in adults to replace current antiretroviral regimens in virologically suppressed patients.

May 2, 2026·1 source
00
Apr 7, 2026

Merck's Experimental HIV Prevention Pill Could Be Manufactured for Under $5 Annually, Researchers Say

Researchers published findings that Merck's experimental HIV prevention pill could be produced for less than $5 per year, urging the company to urgently begin licensing generic production to improve global access.

Apr 7, 2026·1 source
00
Mar 25, 2026

Merck to Acquire Terns Pharmaceuticals for $6.7 Billion

Merck announced it will acquire Terns Pharmaceuticals for $6.7 billion to gain access to a promising leukemia treatment. The deal represents Merck's effort to secure its next generation of blockbuster drugs.

Mar 25, 2026·2 sources
00

Top claims

  • ▪Pharmaceutical companies including Merck and Bayer have expanded into eye disease medicines in recent years by buying early-stage companies
  • ▪Under proposed terms, Johnson & Johnson would pay Ollin Biosciences' backers $2.2 billion in upfront cash and up to $1.2 billion in potential future milestone payments
  • ▪Ollin Biosciences' lead experimental drug, OLN324, is being developed to treat wet age-related macular degeneration and diabetic macular edema

Topics

Wet AMDMergers & acquisitions (M&A)Macular edema treatmentMergers and acquisitionsFinancial tiesPharmaceutical IndustryBiotech innovationTexasDrug developmentClinical trialsMedical researchBiomedical researchDiabetic retinopathyClinical trial endpointsCancer immunotherapyCancer & OncologyCancer treatmentCancer and Cancer TreatmentCancerWomen's healthDrug Policy, Pricing & ApprovalCancer treatment breakthroughsFDA drug approvalCancer TypesMRNA vaccine technologyPersonalized medicineOncologyVaccines and Immunization PolicyImmunotherapyPharmaceutical patentsVaccine development and innovationVaccine developmentDrug pricing policyHealthcare PolicyTrump administration policyInfectious diseaseAntimicrobial resistanceOutbreak monitoring & surveillancePublic healthDrug Approval and Clinical TrialsPharmaU.S.–China relationsChina tech & industrial strategyDrug safetyRare diseasesClinical evaluationClinical Trial Design & EvaluationPublic healthcareCorporate earningsEbola outbreakOutbreak-Driven VaccinationInfectious Disease and OutbreaksGlobal health securityNew drug application (NDA) processCholesterol managementFDA drug approval processCardiovascular health.Bioethicists of life extensionPreventive longevity physicians

Related entities

United StatesChinaMelanomaNetherlandsEuropeImmunologyPfizerDermatologyRare DiseaseOncology